Search clinical trials for: Placebo to BI 144807

Total 1467 results

Boehringer Ingelheim

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 685509 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity

Obesity | Overweight

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid

Healthy

Netherlands
Boehringer Ingelheim

Withdrawn

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids

Asthma
Scleroderma Research Foundation, Inc.
Sanofi; Boehringer Ingelheim

Recruiting

Platform Clinical Study for Conquering Scleroderma (CONQUEST)

Scleroderma | Interstitial Lung Disease Due to Systemic Disease

United States
Boehringer Ingelheim

Active, not recruiting

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Lung Diseases, Interstitial

United States, Spain, China, United Kingdom, Canada, Norway, Korea, Republic of, Belgium, Australia, Germany, Denmark, Singapore, Taiwan, Thailand, Italy, Japan, Finland, Turkey, Croatia, Switzerland, France, Serbia, Netherlands, Mala... and more
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight (SYNCHRONIZE™-1)

Obesity

United States, Korea, Republic of, Belgium, Australia, China, Poland, Japan, Finland, Germany, Canada, Netherlands, New Zealand, Sweden, United Kingdom
Boehringer Ingelheim

Active, not recruiting

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, Spain, China, Canada, Norway, Korea, Republic of, Taiwan, Belgium, Australia, Germany, Denmark, Singapore, Thailand, Italy, Japan, United Kingdom, Switzerland, Croatia, France, Netherlands, Malaysia, New Zealand, Arge... and more
Boehringer Ingelheim

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Schizophrenia

Spain, Korea, Republic of, United Kingdom, Taiwan, United States, Austria, Italy, Germany, Poland, Japan, Canada
Boehringer Ingelheim

Recruiting

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 3006337 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Recruiting

A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Active, not recruiting

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

Bronchiectasis | Cystic Fibrosis

United States, Spain, Belgium, Germany, Italy, Netherlands
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 474121 is Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080

Healthy

Belgium
Boehringer Ingelheim

Active, not recruiting

A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test How Well Men Tolerate Different Doses of BI 3006337

Healthy

Belgium, Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated and How Food Influences the Amount of BI 1569912 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Japan
Boehringer Ingelheim

Completed

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated. (ROBIN)

Diabetic Retinopathy

United States, Spain, Italy, United Kingdom, Austria, Greece, Norway, Portugal
Boehringer Ingelheim

Completed

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Non-alcoholic Fatty Liver Disease

United States, Spain, United Kingdom, Belgium, Canada, Germany, Netherlands, France, Ireland
Boehringer Ingelheim

Completed

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

Idiopathic Pulmonary Fibrosis

Spain, United Kingdom, Italy, Belgium, Germany, Netherlands, Finland, Denmark
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Germany, Denmark, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers

Healthy

Japan
Boehringer Ingelheim

Completed

Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo

Healthy

Germany
Boehringer Ingelheim

Completed

This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Terminated

Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers

Asthma | Rhinitis, Allergic, Perennial

Korea, Republic of
Boehringer Ingelheim

Terminated

Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men

Healthy

Belgium

3

Subscribe